At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
MK-2060drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Safety and Tolerability of Co-administration of MK-2060 and Clopidogrel in Participants With End-Stage Renal Disease on Hemodialysis
In Brief
A Phase 1 clinical trial evaluating MK-2060 for End-Stage Renal Disease and Kidney Failure, Chronic. Completed, enrolled 12 participants across 3 sites in 3 countries.
Detailed Summary
MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in combination with a commonly used P2Y12 receptor inhibitor, clopidogrel, in ESRD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease, Kidney Failure, Chronic
CountriesIsrael, Romania, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionFeb 2023
TodayJul 2026
First PostedApr 19, 2022
Enrollment StartMay 30, 2022
Primary CompletionFeb 14, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.2 years ago
Interventions
MK-2060drug
MK-2060 administered via IV infusion